Harbour BioMed Overview
Pro stress-test →Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. Founded in 2016 with the mission to create breakthrough antibody therapeutics, the company operates a multi-hub innovation platform spanning the US, Europe, and China to advance both internal and partnered programs into clinical development.
Strategic Profile
Pro stress-test →The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour's portfolio spans multiple antibody formats, including conventional monoclonals and heavy chain-only antibodies, as well as engineered bispecifics and next-generation constructs. Recent moves include establishing Nona Biosciences to better empower industry innovators and support collaborators from Idea to IND and a license agreement with Windward Bio for HBM9378, an anti-TSLP fully human antibody for immunological diseases announced in January 2025.
Competitive Landscape
Pro stress-test →Harbour BioMed competes on its proprietary antibody platforms, including Harbour Mice® transgenic mice producing fully human H2L2 and HCAb formats, and HBICE® HCAb-based bispecific immune cell engagers. Direct competitors in the fully human antibody and bispecific space include Genmab, Regeneron, and Amgen, though Harbour's focus on platform licensing and incubation creates a hybrid discovery-as-a-service model distinct from traditional biotech.
Industry Context
Harbour BioMed operates in Fully human antibody therapeutics.
Key facts
Founded: 2016 · Headquarters: Guangzhou, China · Employees: N/A · Revenue: Estimated range not publicly disclosed; private revenue figures unavailable · Market cap: N/A